Advances in hypertension as reported at ACC 2025 include two new therapies that achieve significant blood pressure (BP) reduction, and a comparison of renal denervation methods for resistant BP.

Panelists discuss how immunoglobulin A (IgA) nephropathy treatment has evolved to include supportive care with optimized blood pressure control and renin-angiotensin system blockade as first-line ...

Panelists discuss how immunoglobulin A (IgA) nephropathy significantly impacts patients’ quality of life through chronic symptoms, treatment burden, psychological effects, and the looming threat of ...